I think it's great news. Immuno-oncology is a hot area., the same field as VLA-ASX was in. RGSH4K's pre-cliincal studies with an anti-pd11 inhibitor in could make this a genuine area of development and spark partnering interest. RGH4K was a challenging phase-1 trial to do. RGS has now successfully completed two phase 1 trials in separate areas, both of which were previously backed up by animals trial in both areas. This the work of a genuine biotech, preparing the ground for several value inflections points.
Ann: Positive clinical trial results for cancer vaccine, page-8
Add CMB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
40.0¢ |
Change
-0.020(4.76%) |
Mkt cap ! $4.772M | |||
| Open | High | Low | Value | Volume |
| 42.0¢ | 42.0¢ | 40.0¢ | $2.792K | 6.87K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 7117 | 40.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 42.0¢ | 1910 | 1 |
View Market Depth
| Last trade - 14.13pm 29/07/2024 (20 minute delay) ? |
| CMB (ASX) Chart |